No Data
Scilex Regains Compliance With Nasdaq Requirement for Continued Listing
Scilex Holding Company GAAP EPS of -$0.03, Revenue of $14.34M
Scilex Holding Company Regains Nasdaq Compliance
Express News | Scilex Holding Company Announces That It Regains Nasdaq Compliance Under Listing Rule 5250(C)(1)
Scilex Holding Company Announces Extension of the Maturity Date of Its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025
Scilex Announces Existing Convertible Note Holders Intend To Fund Ex-U.S. Gloperba Licensing From Romeg; Joint Venture With IPMC To Manage Worldwide Licensing And Distribution